Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNO-206 in recurrent extensive small cell lung cancer
NCT00472771Phase 2Withdrawn
- Sponsor
- LadRx
- Start
- May 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldoxorubicin in small cell lung cancer (SCLC), sponsored by LadRx. Planned start May 2008; status: withdrawn.
02
Drugs
aldoxorubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00472771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00472771.